Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Cefepime/Nacubactam	309
Overall Study	STARTED	Aztreonam/Nacubactam	154
Overall Study	STARTED	Imipenem/Cilastatin	151
Overall Study	Treated	Cefepime/Nacubactam	307
Overall Study	Treated	Aztreonam/Nacubactam	152
Overall Study	Treated	Imipenem/Cilastatin	151
Overall Study	Completed Study Drug	Cefepime/Nacubactam	290
Overall Study	Completed Study Drug	Aztreonam/Nacubactam	147
Overall Study	Completed Study Drug	Imipenem/Cilastatin	143
Overall Study	COMPLETED	Cefepime/Nacubactam	284
Overall Study	COMPLETED	Aztreonam/Nacubactam	144
Overall Study	COMPLETED	Imipenem/Cilastatin	139
Overall Study	NOT COMPLETED	Cefepime/Nacubactam	25
Overall Study	NOT COMPLETED	Aztreonam/Nacubactam	10
Overall Study	NOT COMPLETED	Imipenem/Cilastatin	12

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05887908/flow